By ROBERT CYRAN
Allergan, the target of a $52 billion hostile bid from Valeant Pharmaceuticals, is linking stock and option grants to lofty profit goals. It is a bold tactic that should become a norm in M.&A., contends Robert Cyran of Reuters Breakingviews.
Published: July 24, 2014 at 4:00AM
from NYT Business Day http://ift.tt/1ryyOGJ
from WordPress http://ift.tt/1z8lNGo
via Hadi Aboukhater
No comments:
Post a Comment